Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant monoclonal antibody technology.

D L Siegel1

  • 1Department of Pathology & Laboratory Medicine, University of Pennsylvania Medical Center, Room 510 Stellar-Chance Building, 422 Curie Blvd., Philadelphia, PA 19104, USA. siegeld@mail.med.upenn.edu

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|March 14, 2002
PubMed
Summary

Murine hybridoma technology has limitations for human blood group antigen reagents. Novel recombinant antibody technologies offer a solution for developing new diagnostic and therapeutic agents in transfusion medicine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium.

The British journal of dermatology·2019
Same author

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

Bone marrow transplantation·2008
Same author

Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.

Bone marrow transplantation·2006
Same author

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.

Bone marrow transplantation·2005
Same author

Section 5: Structural/genetic analysis of mAbs to blood group antigens. Coordinator's report.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2002
Same author

Isolation of an IgG anti-B from a human Fab-phage display library.

Transfusion·2001

Area of Science:

  • Immunology
  • Biotechnology
  • Transfusion Medicine

Background:

  • Murine hybridoma technology enables monoclonal antibody production but has limitations for human blood group antigen specificity.
  • Murine-derived antibodies can elicit anti-mouse immune responses, limiting therapeutic efficacy.
  • Challenges in human hybridoma formation necessitate alternative methods for producing human antibodies.

Purpose of the Study:

  • To explore novel molecular approaches for human antibody isolation and production.
  • To address the limitations of murine monoclonal antibodies in transfusion medicine.
  • To investigate recombinant methods for generating renewable, low-cost diagnostic and therapeutic reagents.

Main Methods:

  • Repertoire cloning and Fab/phage display technologies are employed.

Related Experiment Videos

  • Rapid cloning of immunoglobulin gene segments to create immune libraries.
  • Selection of antibodies with desired specificities from these libraries.

    • Main Results:

    • These recombinant methods bypass the need for B-cell transformation, tissue culture, or immunized individuals.
    • Facilitates the isolation and production of human antibodies.
    • Enables the creation of immune libraries for antibody selection.

    Conclusions:

    • Recombinant antibody technologies offer a promising alternative to murine hybridomas for transfusion medicine applications.
    • These methods are expected to play a significant role in developing supplies of diagnostic and therapeutic reagents.
    • Anticipated to lead to more effective and safer antibody-based treatments and diagnostics.